

Financial news for ISIS dated on 2015-12-18: Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016

Financial news for ISIS dated on 2015-12-04: Wells Fargo Initiates Coverage on ISIS Pharmaceuticals at Outperform

Financial news for ISIS dated on 2015-11-18: Benzinga's Top Initiations

Financial news for ISIS dated on 2015-11-18: Goldman Sachs Initiates Coverage on ISIS Pharmaceuticals at Neutral, Announces \$65.00 PT

Financial news for ISIS dated on 2015-11-18: Isis Pharmaceuticals May have to Change Name -NY Post

Financial news for ISIS dated on 2015-11-09: Isis Reports Q3 EPS \$(0.30) vs. Est. \$(0.31), Rev. \$49.121M vs. Est. \$52.93M

Financial news for ISIS dated on 2015-11-08: Isis Pharmaceuticals Announces Positive Clinical Data From Lp(a) Lowering Drugs

Financial news for ISIS dated on 2015-11-05: ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray

Financial news for ISIS dated on 2015-11-05: Benzinga's Top Upgrades

Financial news for ISIS dated on 2015-11-05: Isis Pharmaceuticals, Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with FPL

Financial news for ISIS dated on 2015-11-05: Isis Pharmaceuticals, Akcea Therapeutics Report Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy

Financial news for ISIS dated on 2015-11-05: Piper Jaffray Upgrades ISIS Pharmaceuticals to Overweight, Raises PT to \$80.00

Financial news for ISIS dated on 2015-11-03: Isis Announces Positive Preliminary Results on Open-label Phase 2 Study in Patients with TTR Amyloid Cardiomyopathy

Financial news for ISIS dated on 2015-10-30: Isis Pharmaceuticals Initiates Phase 2 Study Of Isis-FXI Rx In Patients With End-Stage Renal Disease On Hemodialysis, Isis Will Be Eligible To Receive \$55M Payment from Bayer Upon Completion of Study, Advancement of Program

Financial news for ISIS dated on 2015-10-27: Top Performing Industries For October 27, 2015

Financial news for ISIS dated on 2015-10-26: ISIS Pharmaceuticals Earns \$5M from GSK for Initiation of Phase 1 Study of ISIS-GSK4-L Rx

Financial news for ISIS dated on 2015-10-15: Isis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN Rx for Patients With SMA Who Have Completed the Phase 3 ENDEAR and CHERISH Studies

Financial news for ISIS dated on 2015-09-22: Benzinga's Top Initiations

Financial news for ISIS dated on 2015-09-22: Barclays Initiates Coverage on ISIS Pharmaceuticals at Equal-weight, Announces \$60.00 PT

Financial news for ISIS dated on 2015-09-11: Isis Pharmaceuticals' Collaboration to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases with AstraZeneca Receives HSR Clearance; To Receive \$65M Payment

Financial news for ISIS dated on 2015-08-04: ISIS Pharma Sees 'Substantially Improving Upon Our Year-End Guidance'

Financial news for ISIS dated on 2015-08-04: Isis Pharma Reports Inline Q2 EPS \$0.29, Sales \$120.4M Vs Est \$112.43M

Financial news for ISIS dated on 2015-08-03: Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOR Cardiovascular, Metabolic And Renal Disease

Financial news for ISIS dated on 2015-08-03: AstraZeneca, Isis Pharmaceuticals to Collaborate to Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases

Financial news for ISIS dated on 2015-07-27: ISIS Pharmaceuticals Announces Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related Cardiomyopathy

Financial news for ISIS dated on 2015-07-22: Isis Announces Positive Clinical Data from Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet

Financial news for ISIS dated on 2015-07-21: Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease

Financial news for ISIS dated on 2015-07-14: ISIS Pharma Reports Earning of \$2.15M for Advancing ISIS-SMN Rx in Children with Spinal Muscular Atrophy

Financial news for ISIS dated on 2015-07-06: Akcea Therapeutics Granted Orphan Drug Designation from the US FDA for Volanesorsen for the Treatment of Familial Chylomicronemia Syndrome

Financial news for ISIS dated on 2015-06-23: ISIS Pharma Still Undervalued, Needham Says

Financial news for ISIS dated on 2015-06-22: Isis Pharmaceuticals Shows Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy

Financial news for ISIS dated on 2015-06-19: 8-K from ISIS Pharma Shows Co. Entered Into Line of Credit Deal with Morgan Stanley Private Bank

Financial news for ISIS dated on 2015-06-11: Highlights From ISIS Pharmaceuticals At Goldman Sachs Healthcare Conference

Financial news for ISIS dated on 2015-06-11: Morning Market Gainers

Financial news for ISIS dated on 2015-06-11: Benzinga's Top #PreMarket Gainers

Financial news for ISIS dated on 2015-06-11: Isis Pharma Reports Increases in Median Event Free Survive and Muscle Function Scores

Financial news for ISIS dated on 2015-06-10: Isis Pharmaceuticals to Host Webcast to Talk Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy

Financial news for ISIS dated on 2015-06-05: UPDATE: Isis Pharma Will Be Paid Immediate \$100M Up-Front Payment from Bayer, Eligible for Up to \$375M in Milestone Payments

Financial news for ISIS dated on 2015-06-05: ISIS Pharma Shares Indicated Up Almost \$3 in Pre-Market Action, Last Traded at \$66.99

Financial news for ISIS dated on 2015-06-05: Isis Pharma Reports License Deal with Bayer for ISIS-FXI Rx Received HSR Approval

Financial news for ISIS dated on 2015-05-05: Isis Pharma Reports Q1 Loss of \$0.14/Share vs Loss of \$0.20/Share Est., Sales \$62.6M vs \$62.7M Est.

Financial news for ISIS dated on 2015-05-05: Benzinga's Top #PreMarket Gainers

Financial news for ISIS dated on 2015-05-04: ISIS Pharmaceuticals Cuts License Deal With Bayer AG

Financial news for ISIS dated on 2015-05-04: Isis Pharma Shares Resume Trade, Stock Now Up ~5%

Financial news for ISIS dated on 2015-05-04: UPDATE: Isis Eligible for Up to \$155M in Near-Term Payments Related to Bayer Deal, Also Eligible for Milestone Payments

Financial news for ISIS dated on 2015-05-04: Isis Pharma Reports Licenses for ISIS-FXI Rx to Bayer

Financial news for ISIS dated on 2015-05-04: Isis Pharma Shares Halted News Pending

Financial news for ISIS dated on 2015-04-30: Isis Pharma Reports Earned \$10M Milestone Payment from Biogen

Financial news for ISIS dated on 2015-04-27: Did The AAN Meeting Affect Biogen, PTC Therapeutics, GW Pharma Or Isis Pharma?

Financial news for ISIS dated on 2015-04-22: Isis Pharma Announces Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis

Financial news for ISIS dated on 2015-04-20: CAR-T Therapy Stocks Hit Hard Following AACR Data

Financial news for ISIS dated on 2015-04-17: It's A Big Weekend For Biotech

Financial news for ISIS dated on 2015-03-23: US Stock Futures Edge Lower Ahead Of

Existing-Home Sales Data

Financial news for ISIS dated on 2015-03-23: UPDATE: Isis Pharma Reports Phase 1 Data on Isis-ANGPTL3Rx Shows Statistical Significant Reductions from Baseline in Lipid Parameters

Financial news for ISIS dated on 2015-03-23: Isis Pharmaceuticals Announces Positive Phase 1 Data on Isis-ANGPTL3Rx

Financial news for ISIS dated on 2015-03-23: Isis Pharma Announces Positive Phase 1 Data on ANGPTL3Rx

Financial news for ISIS dated on 2015-03-19: Small-Cap Growth ETFs Restore Leadership Role

Financial news for ISIS dated on 2015-03-06: Isis Pharma Awarded \$9M Milestone Payment From Biogen Idec

Financial news for ISIS dated on 2015-03-02: Morning Market Losers

Financial news for ISIS dated on 2015-03-02: Benzinga's Top #PreMarket Losers

Financial news for ISIS dated on 2015-03-02: Stifel Nicolaus Downgrades Isis Pharmaceuticals to Hold, Removes \$66.00 PT

Financial news for ISIS dated on 2015-03-02: Brean Capital Downgrades Isis Pharmaceuticals to Hold

Financial news for ISIS dated on 2015-03-02: Isis Pharmaceuticals Earns \$15M Milestone from GSK for Advancing ISIS-TTR Rx

Financial news for ISIS dated on 2015-02-27: Isis Pharma Reports Q4 EPS \$0.25 Vs Est \$0.02, Sales \$84.9M Vs Est \$74.58M

Financial news for ISIS dated on 2015-02-27: Earning & Economic Calendar for Friday February 27, 2015

Financial news for ISIS dated on 2015-02-27: Earnings Scheduled For February 27, 2015

Financial news for ISIS dated on 2015-02-24: ISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels

Financial news for ISIS dated on 2015-02-11: Isis Pharmaceuticals Now Presenting at Leerink Global Healthcare Conference

Financial news for ISIS dated on 2015-02-10: UPDATE: Isis Pharmaceuticals Earns \$5M Milestone Payment from Biogen Idec

Financial news for ISIS dated on 2015-02-05: Isis Pharmaceuticals Earns \$10M Milestone Payment from Biogen Idec for Advancing New Drug Into Development to Treat a Neurodegenerative Disease

Financial news for ISIS dated on 2015-02-04: Benzinga's Top #PreMarket Losers

Financial news for ISIS dated on 2015-02-04: Piper Jaffray Downgrades Isis Pharmaceuticals to Neutral, Lowers PT to \$68.00

Financial news for ISIS dated on 2015-02-03: Isis Reports in Phase 2 Study, Patients Treated With Isis-PTP1BRX Achieved Statistically Significant Reductions in Body Weight, Hemoglobin A1C

Financial news for ISIS dated on 2015-02-03: ISIS Pharma Reports Phase 2 Top Line Results For PTP1B Were Statistically Significant

Financial news for ISIS dated on 2015-01-14: Morning Market Losers

Financial news for ISIS dated on 2015-01-14: Benzinga's Top #PreMarket Losers

Financial news for ISIS dated on 2015-01-14: Isis Pharma Shares Down 2.3% Premarket as Co. Reports Earning of \$7M for Advancing ISIS-SMN Rx in Children with Spinal Muscular Atrophy

Financial news for ISIS dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for ISIS dated on 2015-01-08: Isis Expects to Have Over \$725M Cash at the end of 2014

Financial news for ISIS dated on 2015-01-08: Isis Pharma Says It Plans To Significantly Improve on 2014 Guidance

Financial news for ISIS dated on 2015-01-06: Isis Pharmaceuticals Names Paula Soteropoulos as President, CEO of Akcea Therapeutics

Financial news for ISIS dated on 2015-01-06: Isis Pharmaceuticals Appoints Paula Soteropoulos As President And CEO Of Akcea Therapeutics

Financial news for ISIS dated on 2015-01-05: Isis Pharma Reports Sarah Boyce Named as Chief Business Officer

Financial news for ISIS dated on 2015-01-05: Benzinga's Volume Movers

Financial news for ISIS dated on 2015-01-05: Morning Market Movers

Financial news for ISIS dated on 2015-01-05: Monday #PreMarket Movers: Conatus Pharmaceuticals, Brainstorm Cell Therapeutics And More

Financial news for ISIS dated on 2015-01-05: Isis Pharmaceuticals Shares Rise 4.5% Premarket Following Announcement of Deal with JNJ

Financial news for ISIS dated on 2015-01-05: Isis Pharmaceuticals Announces Collaboration With Janssen on RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract

Financial news for ISIS dated on 2014-12-23: Biotech Stocks Sell Off, ETFs Fall Over 5%

Financial news for ISIS dated on 2014-12-23: Worst Performing Industries For December 23, 2014

Financial news for ISIS dated on 2014-12-23: Mid-Morning Market Update: Markets Mostly Higher; Walgreen Profit Beats Expectations

Financial news for ISIS dated on 2014-12-19: Isis Pharmaceuticals Shares Rise 8% on Positive Jim Cramer/CNBC Comments

Financial news for ISIS dated on 2014-12-17: CNBC's Stock Pops & Drops From December 16

Financial news for ISIS dated on 2014-12-08: 3 Biotech ETFs Rally On Merger News

Financial news for ISIS dated on 2014-12-08: Mid-Afternoon Market Update: Dow Slides Over 100 Points; Oil Futures Down 4%

Financial news for ISIS dated on 2014-12-08: Mid-Day Gainers From December 8: Cubist Pharmaceuticals, Acceleron Pharma, Calithera Biosciences, Cempira, Isis Pharmaceuticals

Financial news for ISIS dated on 2014-12-08: Stifel Nicolaus Maintains Buy on Isis Pharmaceuticals, Inc., Raises PT to \$65.00

Financial news for ISIS dated on 2014-12-07: Isis Pharmaceuticals Positive Phase 2 Data for ISIS-FXI Rx to be Presented Tuesday December 9, 2014 as Late-Breaker at ASH

Financial news for ISIS dated on 2014-12-03: Isis Pharma's ISIS-APOCIII Rx Phase 2 Study Published In The New England Journal of Medicine

Financial news for ISIS dated on 2014-11-25: UPDATE: Isis Pharma Has Earned \$27M Milestone Payment from Biogen Related to Initiation of Phase 3 Study of ISIS-SMN Rx

Financial news for ISIS dated on 2014-11-25: Isis Pharmaceuticals Initiates Phase 3 Study Of ISIS-SMN Rx

Financial news for ISIS dated on 2014-11-20: ISIS-STAT3 Rx And ISIS-AR Rx Data Presented By AstraZeneca At European Cancer Symposium

Financial news for ISIS dated on 2014-11-13: AstraZeneca, Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods

Financial news for ISIS dated on 2014-11-12: Isis Pharmaceuticals Prices Offering of \$425M Of 1.00% Convertible Senior Notes

Financial news for ISIS dated on 2014-11-10: Isis Pharmaceuticals Announces Proposed Offering of \$425M Of Convertible Senior Notes

Financial news for ISIS dated on 2014-11-07: Isis Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.23) vs \$(0.20) Est; Revenue of \$44.10M vs \$44.20M Est

Financial news for ISIS dated on 2014-11-07: Earnings Scheduled For November 7, 2014

Financial news for ISIS dated on 2014-11-05: Isis Pharmaceuticals Earns \$7.5M Milestone Payment From AstraZeneca

Financial news for ISIS dated on 2014-11-05: Isis Pharmaceuticals Earns \$7.5M Milestone Payment from AstraZeneca for Advancement of ISIS-STAT3Rx

Financial news for ISIS dated on 2014-11-03: Isis Pharmaceuticals Earns \$5M In Milestone Payment From GSK for Advancement of ISIS-GSK5 Rx

Financial news for ISIS dated on 2014-10-28: Regulus Prices 5,294,118 Share Offering @\$17.00/Share

Financial news for ISIS dated on 2014-10-10: NASDAQ Slides 1.2%; Manitowoc Shares Dip Following Cautious Outlook

Financial news for ISIS dated on 2014-10-10: Markets Mixed; Fastenal Earnings Meet Estimates

Financial news for ISIS dated on 2014-10-10: Morning Market Movers

Financial news for ISIS dated on 2014-10-10: Benzinga's Top #PreMarket Gainers

Financial news for ISIS dated on 2014-10-10: US Stock Futures Signal Lower Start On Wall Street

Financial news for ISIS dated on 2014-10-10: Isis Pharmaceuticals Reports Encouraging Data from ISIS-SMN Rx Phase 2 Studies in Infants and Children With SMA at WMS

Financial news for ISIS dated on 2014-10-09: US Stock Futures Mixed Ahead Of Jobless Claims Data

Financial news for ISIS dated on 2014-10-09: Isis Pharmaceuticals Earns \$18M From GSK For Advancing ISIS-TTR Rx

Financial news for ISIS dated on 2014-10-01: Isis Pharma Reports \$1.5M Earn from GlaxoSmithKline Related to Advancement of ISIS-GSK4 Rx

Financial news for ISIS dated on 2014-09-17: Isis Pharmaceuticals Shares Move to High; CEO to Appear on Mad Money Tonight

Financial news for ISIS dated on 2014-09-17: Isis Pharmaceuticals Earns \$4M from Achaogen For The Initiation Of A Phase 3 Study Of Plazomicin

Financial news for ISIS dated on 2014-09-02: Antisense Therapeutics ATL1103 Phase II Trial Met Primary Endpoint

Financial news for ISIS dated on 2014-08-28: BMO Capital Maintains Outperform on Isis Pharmaceuticals, Inc., Maintains \$70.00 PT

Financial news for ISIS dated on 2014-08-27: Isis Pharmaceuticals Finally Breaks Out

Financial news for ISIS dated on 2014-08-26: CNBC's Stock Pops & Drops From August 26

Financial news for ISIS dated on 2014-08-26: Winners & Losers From Tuesday, August 26

Financial news for ISIS dated on 2014-08-25: Fast Money Picks For August 26

Financial news for ISIS dated on 2014-08-21: Isis Pharmaceuticals Says on August 21, 2014, First Infant Received First Dose of Isis-SMNRXx In Phase 3 Study; Isis Earned \$18M Milestone Payment from Biogen

Financial news for ISIS dated on 2014-08-21: 8-K from Isis Pharma Shows Co. Earned \$18M Milestone Payment from Biogen Related to ISIS-SMNRx Phase 3 Study

Financial news for ISIS dated on 2014-08-15: US Stock Futures Up Ahead Of Economic Data

Financial news for ISIS dated on 2014-08-15: Isis Pharmaceuticals Earns \$2M Milestone from Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy

Financial news for ISIS dated on 2014-08-12: UPDATE: Laidlow & Co. Initiates Coverage on Isis Pharmaceuticals, Inc. at Buy, Announces \$52.00 PT

Financial news for ISIS dated on 2014-08-12: Laidlow & Co. Initiates Coverage on Isis Pharmaceuticals, Inc. at Buy, Announces \$52.00 PT

Financial news for ISIS dated on 2014-08-04: From Isis Pharma Earnings Conference Call: On Track to Hit \$110M in Milestone Payments This Year, Will Hit \$160M in Sales, Analysts Currently Looking for FY14 Sales ~\$170M

Financial news for ISIS dated on 2014-08-04: Isis Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.10) vs \$(0.13) Est; Revenue of \$57.10M vs \$45.30M Est

Financial news for ISIS dated on 2014-08-01: AMJ

Financial news for ISIS dated on 2014-07-17: Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-APO(a) Rx In Patients With High Lp(a)

Financial news for ISIS dated on 2014-07-16: Isis Pharma Reports Earning of \$1M from GSK Related to Advancing of Isis-TTR RX

Financial news for ISIS dated on 2014-07-09: Markets Edge Higher; Alcoa Profit Beats Street View

Financial news for ISIS dated on 2014-07-02: US Stock Futures Edge Higher Ahead Of ADP Report

Financial news for ISIS dated on 2014-07-02: Isis Pharmaceuticals Earns \$1M From GSK For Advancing Hepatitis B Virus Program

Financial news for ISIS dated on 2014-06-27: Benzinga's Top #PreMarket Losers

Financial news for ISIS dated on 2014-06-26: Isis Pharmaceuticals Shares Fall 8% After-Hours; May be Attributed to Seeking Alpha Article

Financial news for ISIS dated on 2014-06-24: Isis Pharma Wins \$1M from Glaxo for Advancing ISIS-TTR Rx

Financial news for ISIS dated on 2014-06-19: ISIS Pharma Trades Up Premarket; NYT Says Has Potential Heart Attack Drug

Financial news for ISIS dated on 2014-06-19: Morning Market Movers

Financial news for ISIS dated on 2014-06-19: Isis Pharmaceuticals Shares Rise 7% Premarket; May be Attributed to NY Times Article 'In Single Gene, a Path to Fight Heart Attacks', Mentioning Isis

Financial news for ISIS dated on 2014-06-17: UPDATE: Isis Pharmaceuticals Earns \$10M Milestone Payment from Biogen Idec

Financial news for ISIS dated on 2014-06-17: Isis Pharmaceuticals Announces \$10M Milestone Payment from Biogen

Financial news for ISIS dated on 2014-06-16: US Stock Futures Decline Ahead Of Economic Data

Financial news for ISIS dated on 2014-06-16: Isis Pharma Announces Final Phase 2 Data on ISIS-GCGR Rx Showing Significant Reduction in HbA1c for Type-2 Diabetes Patients

Financial news for ISIS dated on 2014-06-10: Morning Market Movers

Financial news for ISIS dated on 2014-06-10: US Stock Futures Down Ahead Of Wholesale Trade Data

Financial news for ISIS dated on 2014-06-10: Isis Pharmaceuticals Earns \$15M Milestone from AstraZeneca for Initiation of Phase 1 Study of ISIS-AR Rx

Financial news for ISIS dated on 2014-06-10: Isis Pharmaceuticals Gets \$15M From AstraZeneca For Phase 1 Study Initiation

Financial news for ISIS dated on 2014-06-09: US Stock Futures Slightly Lower Ahead Of McDonald's Sales Report

Financial news for ISIS dated on 2014-06-09: Isis Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic Dystrophy Type 1, Earns \$15M Milestone from Biogen

Financial news for ISIS dated on 2014-05-27: Stocks To Watch For May 27, 2014

Financial news for ISIS dated on 2014-05-23: Mid-Afternoon Market Update: Nimble Storage Rallies As Pharmacyclics Shows Weakness

Financial news for ISIS dated on 2014-05-23: Mid-Day Market Update: Markets Flatten Out As Hibbett Sports Shows Weakness

Financial news for ISIS dated on 2014-05-23: Mid-Morning Market Update: Markets Show

Strength As RetailMeNot Falls Once Again

Financial news for ISIS dated on 2014-05-23: ISIS Pharma Shares Jump Higher As Piper Jaffray Sees Co.'s Pipeline As 'Most Attractive and Undervalued' In Sector

Financial news for ISIS dated on 2014-05-23: Shares of ISIS Pharma Up Nearly 3% in Premarket, Piper Jaffray Analyst Bullish on Name This Morning

Financial news for ISIS dated on 2014-05-22: Isis Pharmaceuticals Announces Positive Phase 2 Results

Financial news for ISIS dated on 2014-05-20: US Stock Futures Edge Lower Ahead Of Earnings

Financial news for ISIS dated on 2014-05-20: Isis Initiates Phase 1 Study of ISIS-PKK Rx

Financial news for ISIS dated on 2014-05-16: Stocks To Watch For May 16, 2014

Financial news for ISIS dated on 2014-05-15: Isis Pharmaceuticals Announces \$3M Earnings From GlaxoSmithKline For Initiation of a Study

Financial news for ISIS dated on 2014-05-14: Mid-Day Market Update: Fossil Drops On Downbeat Outlook; SunOpta Shares Gain

Financial news for ISIS dated on 2014-05-14: Mid-Morning Market Update: Markets Open Lower; Macy's Posts Rise In Profit

Financial news for ISIS dated on 2014-05-14: Morning Market Movers

Financial news for ISIS dated on 2014-05-14: Benzinga's Top #PreMarket Gainers

Financial news for ISIS dated on 2014-05-14: US Stock Futures Edge Lower Ahead Of Producer Price Index

Financial news for ISIS dated on 2014-05-14: Isis Pharmaceuticals Announces Positive Phase 2 Data on ISIS-GCGR Rx in HbA1c in Patients With Type 2 Diabetes

Financial news for ISIS dated on 2014-05-14: Isis Pharma Offers Phase 2 Data on ISIS-GCGR Rx, Shows Significant Reduction in HbA1c in Patients with Type 2 Diabetes

Financial news for ISIS dated on 2014-05-13: Stocks To Watch For May 13, 2014

Financial news for ISIS dated on 2014-05-07: UPDATE: Piper Jaffray Upgrades ISIS Pharmaceuticals Following Mixed 1Q Results

Financial news for ISIS dated on 2014-05-07: Stocks To Watch For May 07, 2014

Financial news for ISIS dated on 2014-05-06: Spike in Isis May be Attributed to Piper Upgrade

Financial news for ISIS dated on 2014-05-06: Piper Jaffray Upgrades Isis Pharmaceuticals, Inc. to Overweight

Financial news for ISIS dated on 2014-05-06: Isis Pharmaceuticals Shares Spike Higher

Financial news for ISIS dated on 2014-05-06: Isis Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.27) vs \$(0.23) Est; Revenue of \$28.20M vs \$35.12M Est

Financial news for ISIS dated on 2014-05-02: Isis Announces Final Phase 2 Data on ISIS-APOCIII Rx in Patients With Familial Chylomicronemia

Financial news for ISIS dated on 2014-05-01: US Stock Futures Edge Higher Ahead Of Economic Data

Financial news for ISIS dated on 2014-05-01: UPDATE: Isis Reports 69 % Reduction In Triglycerides Achieved

Financial news for ISIS dated on 2014-05-01: Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With High Triglycerides and Type 2 Diabetes

Financial news for ISIS dated on 2014-04-30: Mid-Day Market Update: Twitter Drops On Earnings; Pepco Shares Gain

Financial news for ISIS dated on 2014-04-30: Isis Pharmaceuticals Shares Dropping Further After Company Released Updated Phase 3 Results Tuesday Afternoon; Shares Down Over 12.5 Percent

Financial news for ISIS dated on 2014-04-29: UPDATE: Isis Pharma Offers Updated

Results from ISIS-SMN Rx Clinical Studies

Financial news for ISIS dated on 2014-04-29: Isis Pharma Offers Updated Results from ISIS-SMN Rx Clinical Studies: Says One Infant Died In Connection with Pneumonia 12mg Cohort, SMN Was Well Tolerated in Children Dose as High as 12mg

Financial news for ISIS dated on 2014-04-29: Isis Pharmaceuticals Shares Spike Lower

Financial news for ISIS dated on 2014-04-22: Isis Pharmaceuticals to Present ISIS-SMN Rx Data at 2014 AAN Annual Meeting

Financial news for ISIS dated on 2014-03-31: Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx

Financial news for ISIS dated on 2014-03-24: EARLIER: Isis Announces Antisense Targeting of HBV Produces Dose-Dependent Reductions in Hepatitis B Virus in an Animal Model of HBV

Financial news for ISIS dated on 2014-03-19: US Stock Futures Edge Higher; All Eyes On Fed

Financial news for ISIS dated on 2014-03-19: Isis Initiates Phase 1 Study of ISIS-ANGPTL3 Rx for Hyperlipidemia

Financial news for ISIS dated on 2014-03-03: Isis CEO Crooke: 'Our Novel Insulin Sensitizer Could be Safer Because it's More Specific'

Financial news for ISIS dated on 2014-03-03: Isis CEO Crooke: 'We're Excited About our Diabetes Pipeline Going Into This Year'

Financial news for ISIS dated on 2014-03-03: Isis CEO Crooke: 'We Think Market Opportunity for Kynamro is Substantial'

Financial news for ISIS dated on 2014-03-03: Jim Cramer Interviews CEO Stanley T. Crooke M.D of Isis Pharmaceuticals on Mad Money

Financial news for ISIS dated on 2014-03-03: US Stock Futures Tumble Ahead Of Economic Data

Financial news for ISIS dated on 2014-03-03: ISIS Pharmaceuticals Earns \$1M Milestone Payment from GSK for Advancing ISIS-TTR Rx

Financial news for ISIS dated on 2014-02-28: Isis Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.21) vs \$(0.18) Est; Revenue of \$42.20M vs \$33.19M Est

Financial news for ISIS dated on 2014-02-28: Earnings Scheduled For February 28, 2014

Financial news for ISIS dated on 2014-02-21: Mid-Afternoon Market Update: Groupon Shares Continue to Show Weakness Following Earnings as Isis Pharmaceuticals Rallies

Financial news for ISIS dated on 2014-02-21: Mid-Day Market Update: Acacia Research Shares Decline On Downbeat Results; Emeritus Spikes Higher

Financial news for ISIS dated on 2014-02-21: Isis Pharmaceuticals Shares Rise 6% Premarket on Positive ISIS-SMN Rx Data in Children with SMA

Financial news for ISIS dated on 2014-02-21: US Stock Futures Rise Ahead Of Existing-Home Sales Data

Financial news for ISIS dated on 2014-02-21: Isis Pharmaceuticals Reports Positive Interim Results from ISIS-SMN Rx Multiple Dose Study in Children with SMA

Financial news for ISIS dated on 2014-02-14: Isis Pharma Announces Positive Opinion on European Orphan Drug Designation for ISIS-TTR Rx

Financial news for ISIS dated on 2014-02-13: UPDATE: Isis to Receive \$2M Milestone Payment from Biogen Idec

Financial news for ISIS dated on 2014-02-13: Isis Pharmaceuticals Announces First Child Dosed in Phase 2 Study Evaluating ISIS-SMNRx in Children with SMA

Financial news for ISIS dated on 2014-01-24: Deutsche Bank Adds Isis Pharma to 'Short-Term Buy' List

Financial news for ISIS dated on 2014-01-22: Deutsche Bank Initiates Coverage on Isis Pharmaceuticals, Inc. at Buy, Announces \$60.00 undefined

Financial news for ISIS dated on 2014-01-13: ISIS Pharma Says Will Receive \$7.5M from Alnylam

Financial news for ISIS dated on 2014-01-13: ISIS Pharma Shares Unch Following Comments from CEO Crooke at JP Morgan Healthcare Conference Co. Expecting a 'Ton' of Interest Related to Partnerships for Triglyceride Drug

Financial news for ISIS dated on 2014-01-13: Isis Announces Positive Decision on European Orphan Drug Designation for ISIS-APOCIII Rx

Financial news for ISIS dated on 2013-12-02: Isis Pharmaceuticals Earns \$2M Milestone Payment from GSK for Advancement of ISIS-TTR Rx

Financial news for ISIS dated on 2013-11-27: UPDATE: Piper Jaffray Assumes Coverage on ISIS Pharmaceuticals as Company's Antisense Platform Continues to Advance

Financial news for ISIS dated on 2013-11-26: Piper Jaffray Upgrades Isis Pharmaceuticals, Inc. to Neutral

Financial news for ISIS dated on 2013-11-26: Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-GSK3 Rx, Earns \$3M Milestone Payment From GSK

Financial news for ISIS dated on 2013-11-22: Isis Pharmaceuticals Announces Plan Investigate Higher Dose of ISIS-SMN Rx in Children with Spinal Muscular Atrophy

Financial news for ISIS dated on 2013-11-18: Isis Pharmaceuticals Announces Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx

Financial news for ISIS dated on 2013-11-16: Isis Pharmaceuticals Announces Positive Phase 1 Results with ISIS-APO(a) Rx

Financial news for ISIS dated on 2013-11-15: Isis Pharma Wins \$5M in Milestone Payment from Glaxo for Advancement of ISIS-GSK4 Rx

Financial news for ISIS dated on 2013-11-15: Isis Earns \$5M Milestone Payment from GSK

Financial news for ISIS dated on 2013-11-12: Isis Pharmaceuticals Announces \$1.5M Milestone Payment from Biogen Related to Phase 2 study of ISIS-SMNRx

Financial news for ISIS dated on 2013-11-05: Isis Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.21) vs \$(0.27) Est; Revenue of \$23.60M vs \$19.82M Est

Financial news for ISIS dated on 2013-10-04: UPDATE: J.P. Morgan Initiates Coverage on Isis Pharmaceuticals, Awaiting Better Entry Point

Financial news for ISIS dated on 2013-10-04: JP Morgan Initiates Coverage on Isis Pharmaceuticals, Inc. at Neutral, Announces \$37.00 PT

Financial news for ISIS dated on 2013-10-03: ISIS Pharm Advances Phase 2 Study of ISIS-SMN Rx in Infants, Says Earns \$2M Milestone

Financial news for ISIS dated on 2013-10-02: Pharmaceutical Industry Expected To Collect Billions From Obamacare

Financial news for ISIS dated on 2013-09-23: Market Wrap For Monday, September 23: Markets Unmoved Despite Kenyan Terror

Financial news for ISIS dated on 2013-09-23: Mid-Afternoon Market Update: Celldex Therapeutics Rallies as Pandora Drops

Financial news for ISIS dated on 2013-09-23: Mid-Day Market Update: Oil Futures Tumble For Third Day in a Row; BlackBerry Shares Decline

Financial news for ISIS dated on 2013-09-23: Mid-Morning Market Update: Markets Edge Lower; Apple Sells 9M New iPhones In First Weekend

Financial news for ISIS dated on 2013-09-21: Isis Reports Positive Phase 2 Data on ISIS-APOCIII Rx in Patients with Familial Chylomicronemia

Financial news for ISIS dated on 2013-09-19: Isis Reports Follow-Up Data from Phase 1 ISIS-SMN Rx SMA Study

Financial news for ISIS dated on 2013-09-09: Market Wrap for Monday, September 9: Nasdaq Bounces To 13 Year High

Financial news for ISIS dated on 2013-09-09: Mid-Afternoon Market Update: Markets Lead by the NASDAQ as Various Health Names Drop

Financial news for ISIS dated on 2013-09-09: Mid-Day Market Update: Dow Rises Over 100 Points; Apple Shares Gain

Financial news for ISIS dated on 2013-09-09: Hearing Piper Cautious on Isis Pharmaceuticals

Financial news for ISIS dated on 2013-09-09: Benzinga's Volume Movers

Financial news for ISIS dated on 2013-09-09: Mid-Morning Market Update: Markets Open Higher; Koch Industries To Acquire Molex For \$38.50/Share

Financial news for ISIS dated on 2013-09-09: Goldman Sachs Reiterates Neutral Rating, \$26 PT on ISIS Pharmaceuticals Following Investor Feedback

Financial news for ISIS dated on 2013-09-09: Benzinga's Top Pre-Market Gainers

Financial news for ISIS dated on 2013-09-09: US Stock Futures Up Ahead Of Consumer Credit Data

Financial news for ISIS dated on 2013-09-09: Biogen, Isis Pharmaceuticals Announce Strategic Collaboration

Financial news for ISIS dated on 2013-09-04: Benzinga's Top Initiations

Financial news for ISIS dated on 2013-09-04: Goldman Sachs Initiates Coverage on Isis Pharmaceuticals, Inc. at Neutral, Announces \$26.00 PT

Financial news for ISIS dated on 2013-09-03: Benzinga's Top Pre-Market Gainers

Financial news for ISIS dated on 2013-08-31: Isis Reports Positive Interim Phase 2 Data on ISIS-APOCIII Rx

Financial news for ISIS dated on 2013-08-26: These ETFs House The Next Biotech Takeover Targets

Financial news for ISIS dated on 2013-08-11: Barron's Recap: The Changing World Of MLPs

Financial news for ISIS dated on 2013-08-06: ISIS Pharmaceuticals Registers 3.5 Million shares For Sale At \$28.38

Financial news for ISIS dated on 2013-08-06: Isis Pharma Reports Q2 Loss \$0.09/Share vs Loss of \$0.21/Share, Sales \$38.1M vs \$26.8M Est.

Financial news for ISIS dated on 2013-08-05: Needham Says Buy the Dip in Isis Pharma, Didn't See Favorable Chance CRP Would Be Indicated for RA

Financial news for ISIS dated on 2013-08-05: Isis Pharmaceuticals Reports Phase 2 Data from Isis-CRP Rx RA Study

Financial news for ISIS dated on 2013-07-23: UPDATE: Piper Jaffray Downgrades ISIS Pharmaceuticals on Limited Ownership of Pipeline

Financial news for ISIS dated on 2013-07-23: UPDATE: Piper Jaffray Downgrades Isis Pharma to Underweight

Financial news for ISIS dated on 2013-07-23: Piper Jaffray Downgrades Isis Pharmaceuticals, Inc. to Underweight, Raises PT to \$20.00

Financial news for ISIS dated on 2013-07-22: Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions of ApoC-III and Triglycerides in Patients With High Triglycerides Taking Fibrates

Financial news for ISIS dated on 2013-07-22: Isis Reports Positive Phase 2 Data on ISIS-APOCIII Rx

Financial news for ISIS dated on 2013-07-02: BMO Says Biotech Sector Could See Upside from M&A, Offers Multiple Attractive Targets

Financial news for ISIS dated on 2013-07-02: Pfizer and Novartis Could Be Eyeing Onyx (PFE, NVS, ONXX)

Financial news for ISIS dated on 2013-06-25: Breau Castleman Joins Isis Pharmaceuticals' Board of Directors

Financial news for ISIS dated on 2013-06-25: UPDATE: Jefferies Raises PT on ISIS Pharmaceuticals Following ApoCIIIRx Reduction

Financial news for ISIS dated on 2013-06-25: Jefferies Maintains Underperform on Isis Pharmaceuticals, Inc., Raises PT to \$9.00

Financial news for ISIS dated on 2013-06-24: Market Wrap for Monday, June 24: Stocks Continue Slide to Start Trading Week

Financial news for ISIS dated on 2013-06-24: Mid-Afternoon Market Update: Markets Recovering; Walter Energy Gets Crushed

Financial news for ISIS dated on 2013-06-24: Afternoon Market Movers

Financial news for ISIS dated on 2013-06-24: Mid-Day Market Update: Dow Tumbles 200 Points, Isis Pharma Shares Spike Higher

Financial news for ISIS dated on 2013-06-24: Benzinga's Volume Movers

Financial news for ISIS dated on 2013-06-24: Mid-Morning Market Update: Markets Fall, Tenet Healthcare To Acquire Vanguard Health

Financial news for ISIS dated on 2013-06-24: Stocks Hitting 52-Week Highs

Financial news for ISIS dated on 2013-06-24: Isis Pharma Shares Rally Following Phase 2 Data on ISIS-APOCIII

Financial news for ISIS dated on 2013-06-24: Benzinga's Top Pre-Market Gainers

Financial news for ISIS dated on 2013-06-12: Stocks Hitting 52-Week Highs

Financial news for ISIS dated on 2013-06-10: Xenon Licenses Antisense Drug XEN701 from Isis

Financial news for ISIS dated on 2013-06-06: Isis Pharma Announces \$6M Payment from AstraZeneca

Financial news for ISIS dated on 2013-06-03: Isis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients With Cancer

Financial news for ISIS dated on 2013-06-03: Isis Pharma Announces \$10M Milestone Payment from AstraZeneca for ISIS-AR

Financial news for ISIS dated on 2013-05-31: Isis Pharma Announces Underwriters' Exercise Option for Shares to Cover Overallotments, Underwriters' Bought an Added 617.87K Shares

Financial news for ISIS dated on 2013-05-09: Isis Pharmaceuticals Earns \$3.5M from Biogen Idec

Financial news for ISIS dated on 2013-05-08: Isis Pharmaceuticals Prices 9M Share Offering at \$19/Share

Financial news for ISIS dated on 2013-05-07: Isis Pharmaceuticals Announces Proposed Public 9M Share Offering of Common Stock

Financial news for ISIS dated on 2013-05-07: Isis Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.02), Inline

Financial news for ISIS dated on 2013-05-06: Isis Pharmaceuticals Initiates Clinical Study of ISIS-STAT3 Rx in Liver Cancer Patients

Financial news for ISIS dated on 2013-04-24: Stifel Nicolaus Maintains Buy on Isis Pharmaceuticals, Inc., Raises PT to \$27.00

Financial news for ISIS dated on 2013-04-23: ISIS Pharm Begins Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy

Financial news for ISIS dated on 2013-04-19: UPDATE: BMO Capital Markets Raises PT on Isis Pharmaceuticals Following Development Head Meeting

Financial news for ISIS dated on 2013-04-19: BMO Capital Maintains Outperform on Isis Pharmaceuticals, Inc., Raises PT to \$31.00

Financial news for ISIS dated on 2013-04-08: Isis Pharma Shares Resume, Up 1%

Financial news for ISIS dated on 2013-04-08: Shares of Isis Pharma to Resume Trade at 9:45AM EST

Financial news for ISIS dated on 2013-04-08: UPDATE: Roche, Isis Pharma Partner Against Huntington's Disease, Roche to Pay \$30M Upfront

Financial news for ISIS dated on 2013-04-08: Roche, Isis Pharma Announce Alliance for Huntington's Disease, Roche to Make Upfront Payments \$30M

Financial news for ISIS dated on 2013-04-08: Isis Pharma Halted News Pending

Financial news for ISIS dated on 2013-04-03: A Peek Into The Market Before The Trading Starts

Financial news for ISIS dated on 2013-04-03: Isis Initiates Phase 1 Study of ISIS-APOA Rx to Treat Atherosclerosis

Financial news for ISIS dated on 2013-04-01: Isis Pharma Issues Data Showing Antisense Targeting of ApoC-III Significantly Reduces ApolC-III, Triglycerides

Financial news for ISIS dated on 2013-03-22: Isis Pharma Issues Update on CHMP Opinion on KYNAMRO

Financial news for ISIS dated on 2013-03-21: BMO Capital Maintains Outperform on Isis Pharmaceuticals, Inc., Raises PT to \$22.00

Financial news for ISIS dated on 2013-03-13: Isis Pharma Issues Clinical Data Demonstrating Blunting of Severe Increases in CRP

Financial news for ISIS dated on 2013-02-28: Isis Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.03) vs \$(0.23) Est; Revenue of \$19.90M

Financial news for ISIS dated on 2013-01-30: Market Wrap for Wednesday, January 30: Stocks Fall as Economy Contracts in Q4

Financial news for ISIS dated on 2013-01-30: UPDATE: Piper Jaffray Raises PT to \$11 on ISIS Pharmaceuticals on KYNAMRO Approval

Financial news for ISIS dated on 2013-01-30: Mid-Day Market Update: BlackBerry 10 Release Sends Shares Lower, Isis Pharma Boosts

Financial news for ISIS dated on 2013-01-30: Isis and Sanofi's Drug OK'd to Treat Inherited Cholesterol Disease

Financial news for ISIS dated on 2013-01-30: Isis Surges on FDA Approval of KYNAMRO

Financial news for ISIS dated on 2013-01-30: Piper Jaffray Maintains Neutral on Isis Pharmaceuticals, Inc., Raises PT to \$11.00

Financial news for ISIS dated on 2013-01-30: UPDATE: Jefferies Reiterates Underperform Rating, Raises PT on ISIS Pharmaceuticals

Financial news for ISIS dated on 2013-01-30: Jefferies Maintains Underperform on Isis Pharmaceuticals, Inc., Raises PT to \$7.00

Financial news for ISIS dated on 2013-01-29: Isis Pharmaceuticals to Provide Update on FDA Approval of KYNAMRO, 09:30 AM ET, Wednesday, January 30, 2013

Financial news for ISIS dated on 2013-01-14: UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on Isis Pharmaceuticals

Financial news for ISIS dated on 2013-01-14: BMO Capital Maintains Outperform on Isis Pharmaceuticals, Inc., Raises PT to \$17.00

Financial news for ISIS dated on 2013-01-08: Mid-Afternoon Market Update: Markets Fall Further, Isis Pharma Rallies

Financial news for ISIS dated on 2013-01-02: Isis Pharma Names Elizabeth Hougen New CFO, Says Parshall to Remain as COO

Financial news for ISIS dated on 2012-12-24: Aegerion Pharmaceuticals Wins Approval for Cholesterol Drug

Financial news for ISIS dated on 2012-12-14: Piper Jaffray Maintains Neutral on Isis Pharmaceuticals, Inc., Lowers PT to \$9.00

Financial news for ISIS dated on 2012-12-14: Benzinga's Top Pre-Market Losers

Financial news for ISIS dated on 2012-12-14: Genzyme, Isis Pharma Say CHMP, EMA Adopted Negative Opinion on Kynamro

Financial news for ISIS dated on 2012-12-13: Isis Pharma Announces Fast Track Designation for ISIS-TTR Rx for Treatment of Patients with FAP

Financial news for ISIS dated on 2012-12-11: Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer

Financial news for ISIS dated on 2012-12-10: Piper Jaffray Reiterates Neutral Rating,

\$10 PT on ISIS Pharmaceuticals

Financial news for ISIS dated on 2012-12-10: Biogen, Isis Pharma Announce Collaboration for Antisense Programs

Financial news for ISIS dated on 2012-12-07: Isis Pharma Posts Positive Phase 1 Data on Three Drugs in Development to Treat Metabolic Disorders

Financial news for ISIS dated on 2012-12-02: BioMarin, Prestige Brands and Other Top Performing Health Care Stocks in November

Financial news for ISIS dated on 2012-11-09: Mid-Afternoon Market Update: Markets Slow Their Rally; Groupon Trades Down on Massive Volume

Financial news for ISIS dated on 2012-11-09: Mid-Morning Market Update: Markets Rallying; J.C. Penney Misses Big On Earnings

Financial news for ISIS dated on 2012-11-07: UPDATE: Jefferies & Company Reiterates Underperform Rating, Lowers PT on ISIS Pharmaceuticals

Financial news for ISIS dated on 2012-11-07: Jefferies & Company Maintains Isis Pharmaceuticals at Underperform, Lowers PT from \$8 to \$7

Financial news for ISIS dated on 2012-11-06: Isis Pharmaceuticals Reports Q3 EPS \$-0.37 vs \$-0.26 Est; Revenues \$11.6M May Not Compare to \$23.11M Est

Financial news for ISIS dated on 2012-10-29: Isis Initiates Phase 2 Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery

Financial news for ISIS dated on 2012-10-23: Isis Pharmaceuticals To Receive \$1.1 Million From Alnylam

Financial news for ISIS dated on 2012-10-23: Isis on Mad Money with Jim Cramer Tonight

Financial news for ISIS dated on 2012-10-19: Benzinga Mid-Morning Market Update

Financial news for ISIS dated on 2012-10-19: Jefferies & Company Maintains Isis Pharmaceuticals at Underperform, Lowers PT from \$10 to \$8

Financial news for ISIS dated on 2012-10-19: Isis Pharmaceuticals Rises 10% Pre-Market on FDA Panel Recommendation of KYNAMRO for Homozygous Familial Hypercholesterolemia

Financial news for ISIS dated on 2012-10-18: UPDATE: Isis Pharmaceuticals Rises 15% After-Hours on Positive FDA Panel Vote

Financial news for ISIS dated on 2012-10-18: Isis Pharmaceuticals Resumes Trading

Financial news for ISIS dated on 2012-10-18: FDA Advisory Committee Votes to Recommend Isis' KYNAMRO

Financial news for ISIS dated on 2012-10-18: Benzinga Mid-Afternoon Market Update

Financial news for ISIS dated on 2012-10-18: Benzinga Mid-Day Market Update

Financial news for ISIS dated on 2012-10-18: Benzinga Mid-Morning Market Update

Financial news for ISIS dated on 2012-10-18: ISIS Pharmaceuticals Stock Trading Halted Pending FDA Panel

Financial news for ISIS dated on 2012-10-17: Benzinga Mid-Afternoon Market Update

Financial news for ISIS dated on 2012-10-17: Benzinga Mid-Day Market Update

Financial news for ISIS dated on 2012-10-17: Benzinga Mid-Morning Market Update

Financial news for ISIS dated on 2012-10-17: Summer Street Downgrades Isis Pharmaceuticals from Buy to Neutral

Financial news for ISIS dated on 2012-10-16: Benzinga Mid-Afternoon Market Update

Financial news for ISIS dated on 2012-10-16: UPDATE: Piper Jaffray Downgrades ISIS Pharmaceuticals to Neutral on FDA Briefing

Financial news for ISIS dated on 2012-10-16: Benzinga Mid-Morning Market Update

Financial news for ISIS dated on 2012-10-16: Morning Market Losers

Financial news for ISIS dated on 2012-10-16: Piper Jaffray Downgrades Isis Pharmaceuticals from Overweight to Neutral, Lowers PT from \$18 to \$10

Financial news for ISIS dated on 2012-10-16: Benzinga's Top Pre-Market Losers

Financial news for ISIS dated on 2012-10-15: Benzinga Mid-Afternoon Market Update

Financial news for ISIS dated on 2012-10-15: Benzinga Mid-Day Market Update

Financial news for ISIS dated on 2012-10-15: Benzinga Mid-Morning Market Update

Financial news for ISIS dated on 2012-10-15: Benzinga's Top Pre-Market Gainers

Financial news for ISIS dated on 2012-10-11: Isis Investment In Regulus Valued At \$28 Million At Completion Of Regulus Initial Public Offering

Financial news for ISIS dated on 2012-09-13: Isis Pharma Completes Redemption of \$162.5M in Senior Notes

Financial news for ISIS dated on 2012-09-06: JMP Securities Initiates Coverage on Isis Pharmaceuticals at Market Perform

Financial news for ISIS dated on 2012-09-06: JMP Securities on Isis Pharmaceuticals

Financial news for ISIS dated on 2012-09-05: Watchlist for Wednesday, September 5

Financial news for ISIS dated on 2012-09-05: Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Cash

Financial news for ISIS dated on 2012-08-28: Isis Pharma to Receive \$1.4M from Alnylan

Financial news for ISIS dated on 2012-08-20: Regulus Files Registration Statement for Proposed Initial Public Offering

Financial news for ISIS dated on 2012-08-07: Canaccord Maintains Isis Pharmaceuticals at Hold, Raises PT from \$9 to \$11

Financial news for ISIS dated on 2012-08-06: Isis Pharmaceuticals Announces Proposed Offering of \$175 Million of Convertible Senior Notes

Financial news for ISIS dated on 2012-08-06: Isis Pharmaceuticals Reports Q2 EPS \$-0.01 vs \$-0.10 Est; Revenues \$47.3M vs \$40.06M Est

Financial news for ISIS dated on 2012-08-03: European Regulatory Authorities Approve Isis' Manufacturing Facility

Financial news for ISIS dated on 2012-07-30: UPDATE: Stifel Nicolaus Raises PT to \$17 on ISIS Pharmaceuticals on Pipeline Confidence

Financial news for ISIS dated on 2012-07-30: Stifel Nicolaus Maintains Isis Pharmaceuticals at Buy, Raises PT from \$11 to \$17

Financial news for ISIS dated on 2012-07-19: Equity Moves on Sell-Side Sentiment for July 19, 2012

Financial news for ISIS dated on 2012-07-19: UPDATE: Jefferies Downgrades ISIS Pharmaceuticals from Buy to Underperform

Financial news for ISIS dated on 2012-07-19: Jefferies & Company Downgrades ISIS Pharmaceuticals from Buy to Underperform

Financial news for ISIS dated on 2012-07-18: UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on Isis Pharmaceuticals

Financial news for ISIS dated on 2012-07-18: Piper Jaffray Maintains Isis Pharmaceuticals at Overweight, Raises PT from \$15 to \$18

Financial news for ISIS dated on 2012-07-02: Isis Pharmaceuticals Heavy Put Volume May be Attributed to Seeking Alpha Article on Company's Cholesterol Drug

Financial news for ISIS dated on 2012-07-02: Option Alert: Isis Pharmaceuticals Put Volume at 1,668% of Average, Currently \$12.78

Financial news for ISIS dated on 2012-06-29: Biogen Idec, Isis To Develop Antisense Drug For Treatment Of Myotonic Dystrophy Type 1; Biogen Idec Says Isis Will Receive Upfront Payment Of \$12M

Financial news for ISIS dated on 2012-05-29: Genzyme and Isis Announce Filing of U.S.

NDA for KYNAMRO in Homozygous Familial Hypercholesterolemia

Financial news for ISIS dated on 2012-05-22: Needham Initiates Coverage on Isis Pharmaceuticals at Buy, Announces PT of \$14

Financial news for ISIS dated on 2012-05-08: Isis Pharmaceuticals Reports Q1 EPS \$-0.24 vs \$-0.26 Est; Revenues \$23.2M vs \$22.72M Est

Financial news for ISIS dated on 2012-05-04: Isis Initiates Phase 2 Study of ISIS-APOCIIIIRx in Patients with Hypertriglyceridemia

Financial news for ISIS dated on 2012-05-01: Benzinga's Top Upgrades with Color for May 1, 2012

Financial news for ISIS dated on 2012-05-01: UPDATE: Piper Jaffray Upgrades ISIS Pharmaceuticals; Raises PT

Financial news for ISIS dated on 2012-05-01: Piper Jaffray Upgrades Isis Pharmaceuticals from Neutral to Overweight, Raises PT from \$10 to \$15

Financial news for ISIS dated on 2012-03-29: Genzyme and Isis Announce Submission of U.S. NDA for KYNAMRO in Homozygous Familial Hypercholesterolemia

Financial news for ISIS dated on 2012-03-26: Canaccord Initiates Coverage on Isis Pharmaceuticals at Hold, Announces PT of \$9

Financial news for ISIS dated on 2012-03-07: Piper Jaffray: ISIS Pharmaceuticals Initiates Phase I Study

Financial news for ISIS dated on 2012-03-07: Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx

Financial news for ISIS dated on 2012-02-29: Isis Pharmaceuticals Reports Q4 EPS \$(0.20) vs \$(0.18) Est; Revenues \$32.40M vs \$30.30M Est

Financial news for ISIS dated on 2012-01-05: ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein

Financial news for ISIS dated on 2012-01-04: Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy

Financial news for ISIS dated on 2011-12-20: Isis Initiates Phase 1 Clinical Trial of ISIS-FGFR4Rx a Peripherally Acting Drug to Treat Obesity

Financial news for ISIS dated on 2011-12-15: Isis Updates KYNAMRO Submission Timeline

Financial news for ISIS dated on 2011-12-12: Isis Reports Positive Phase 1 Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without

Financial news for ISIS dated on 2011-12-06: Isis Reports Positive Phase 1 Data Demonstrating ISIS-APOCIIIIRx Produces Significant Reductions in apoC-III Protein Levels

Financial news for ISIS dated on 2011-11-30: Piper Jaffray Reiterates Neutral, \$10 Target on ISIS Pharmaceuticals

Financial news for ISIS dated on 2011-11-30: United States Patent and Trademark Office Upholds Key Santaris Pharma A/S LNA Patents in Two Re-Examination Cases Brought by Isis Pharmaceuticals

Financial news for ISIS dated on 2011-11-22: UPDATE: Isis to Receive Up to \$14M from Pfizer for Its Acquisition of Excaliard Pharmaceuticals

Financial news for ISIS dated on 2011-11-07: End-of-Day Market Summary for November 7, 2011

Financial news for ISIS dated on 2011-11-07: Isis Pharmaceuticals Reports Q3 EPS \$(0.27) vs \$(0.20) Est; Revenues \$20.70M vs \$25.33M Est

Financial news for ISIS dated on 2011-11-02: Isis Initiates Phase 1 Studies with Isis-GCRRx and Isis-GCCRRx to Treat Type 2 Diabetes

Financial news for ISIS dated on 2011-09-23: Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma

Financial news for ISIS dated on 2011-09-09: Notable Put Options Activity in Isis Pharmaceuticals

Financial news for ISIS dated on 2011-09-07: Engulfed 09-06-2011

Financial news for ISIS dated on 2011-08-19: Notable Call Options Activity in Isis Pharmaceuticals

Financial news for ISIS dated on 2011-07-21: Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes

Financial news for ISIS dated on 2011-06-17: Piper Jaffray Updates On ISIS Following Shareholders Meeting

Financial news for ISIS dated on 2011-05-19: Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns \$5 Million Milestone Payment From GlaxoSmithKline

Financial news for ISIS dated on 2011-05-18: GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term

Financial news for ISIS dated on 2011-04-07: Calls Purchased on Isis Pharmaceuticals (ISIS)

Financial news for ISIS dated on 2011-03-09: Isis Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference

Financial news for ISIS dated on 2011-03-01: Citi Reports Uneventful 4Q For Isis Pharmaceuticals

Financial news for ISIS dated on 2011-03-01: Piper Jaffray Maintains \$10 PT, Neutral Rating On ISIS

Financial news for ISIS dated on 2011-02-28: Isis Reports Q4 EPS of \$(0.14) vs. \$(0.22)

Financial news for ISIS dated on 2011-02-28: Isis Reports Financial Results and Highlights for 2010

Financial news for ISIS dated on 2011-01-12: Isis CEO Expects Sanofi To Buy Genzyme (SNY, GENZ)

Financial news for ISIS dated on 2011-01-06: Isis Pharmaceuticals Develops Two New Drugs

Financial news for ISIS dated on 2011-01-04: Isis Initiates Phase 2 Program of ISIS-EIF4ERx in Cancer

Financial news for ISIS dated on 2010-11-16: Zacks Analyst Blog Highlights: Isis Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Johnson & Johnson and Genzyme - Press Releases

Financial news for ISIS dated on 2010-11-15: Loss Widens at Isis Pharma - Analyst Blog

Financial news for ISIS dated on 2010-11-04: Isis Reports Financial Results and Highlights for Third Quarter 2010: Loss of \$0.13 Per Share

Financial news for ISIS dated on 2010-09-29: Upside Purchased on Isis Pharma (ISIS)

Financial news for ISIS dated on 2010-09-02: Piper Jaffray Sees 25% Upside In ISIS Pharmaceuticals (ISIS)

Financial news for ISIS dated on 2010-08-31: Genzyme Rejects Sanofi Offer - Analyst Blog

Financial news for ISIS dated on 2010-08-16: Isis Loss Widens - Analyst Blog

Financial news for ISIS dated on 2010-08-05: ALNY's 2Q Loss Down on Lower Costs - Analyst Blog

Financial news for ISIS dated on 2010-08-05: Piper Jaffray Downgrading Shares of ISIS Pharmaceuticals (ISIS)

Financial news for ISIS dated on 2010-06-21: Piper Jaffray Reiterates Overweight Rating On ISIS Pharmaceuticals (ISIS)

Financial news for ISIS dated on 2010-06-07: Top 5 Small-Cap NASDAQ Stocks In The Healthcare Sector With The Highest Cash (ONXX, ISIS, MYGN, CBST, VPHM)

Financial news for ISIS dated on 2010-05-21: Cantor Recommends Isis Pharma And Star Bulk Carriers (ISIS, SBLK)

Financial news for ISIS dated on 2010-05-20: Piper Jaffray Maintains Overweight Rating For ISIS

Financial news for ISIS dated on 2010-05-06: Isis Pharmaceuticals Announces Net Operating Loss (ISIS)

Financial news for ISIS dated on 2010-05-03: Benzinga's Top Pre-Market Losers (ISIS, OMNI, NLST, ATPG, TRMA)

Financial news for ISIS dated on 2010-04-15: ISIS' Mipomersen Continues To Be The Main Driver

Financial news for ISIS dated on 2010-04-05: Barron's; Amegen And Spectrum Top Pharma Picks (AMGN, ISIS, SPPI, GENZ)

Financial news for ISIS dated on 2010-03-31: ISIS Collaboration With GlaxoSmithKline Not Favorable

Financial news for ISIS dated on 2010-03-31: Benzinga's Volume Movers (ISIS, KMGB, CLNE, SYNA, GIVN)

Financial news for ISIS dated on 2010-03-31: Benzinga's Top Pre-Market Gainers (ARQL, AIXG, ISIS, ORCT)

Financial news for ISIS dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for ISIS dated on 2010-03-15: Benzinga's Top Pre-Market Gainers (PVH, AMLN, CHRD, ISIS, NVAX)

Financial news for ISIS dated on 2010-03-08: Cantor Fitzgerald Reiterates Isis Pharmaceuticals (ISIS) Buy Rating

Financial news for ISIS dated on 2010-03-05: Benzinga's News Roundup (GPPE, COF, ISIS, BHI, TIVO)

Financial news for ISIS dated on 2010-02-16: Benzinga's Top Pre-Market Losers (ISIS, ULTI, TUES, MU, EXBD)

Financial news for ISIS dated on 2010-02-12: ISIS Downgraded On Safety Concerns Regarding Mipomersen

Financial news for ISIS dated on 2010-02-11: Stocks That Created New 52-Week Lows (AFCEB, BFSB, FTEK, ICOPW, ISIS)

Financial news for ISIS dated on 2010-02-11: ISIS Pharmaceuticals, Inc. (ISIS) Maintains A Buy Rating

Financial news for ISIS dated on 2010-02-11: Benzinga's Top Pre-Market Losers (ISIS, ULTI, TUES, MU, EXBD)

Financial news for ISIS dated on 2010-02-10: Benzinga's Top Losers (ISIS, ULTI, PKY, KAZ, DF)

Financial news for ISIS dated on 2010-01-12: ISIS Rides On Cardio (ISIS)

Financial news for ISIS dated on 2009-12-16: Advancing R&D Pipeline To Boost Isis (ISIS) Prospects

Financial news for ISIS dated on 2009-12-14: Stocks That Formed New 52-Week Lows (COWN, EPG, FCAL, DISK, ISIS)

Financial news for ISIS dated on 2009-12-11: New 52-week Low Stocks (COCO, ISIS, ETRM, ALJ)

Financial news for ISIS dated on 2009-12-09: New 52-week Low Stocks (ECA, ISIS, GIGM, PTY)

Financial news for ISIS dated on 2009-12-08: New 52-week Low Stocks (COCO, ISIS, SWS, LAB)

Financial news for ISIS dated on 2009-11-18: Morgan Joseph maintains "Buy" for ISIS Pharmaceuticals (NASDAQ:ISIS)

Financial news for ISIS dated on 2009-08-18: Major Broadcasters, Studio Productions, Rental Companies and Educators Invest in Avid Solutions

Financial news for ISIS dated on 2009-08-07: RothmanResearch.com Stock Review for CRA, HOTT, ISIS, LLTC, NWSA and NUAN

